stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Operating cash flow
NewAmsterdam Pharma Company N.V.'s operating cash flow for fiscal 2025 was −$147.8M, compared with −$158.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$150.5M. Over the past ten years it has ranged from −$158.6M (fiscal 2024) to $10.7M (fiscal 2022); the current reading is higher than 29% of that period. NewAmsterdam Pharma Company N.V. ranks 504th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$147.8M | — |
| FY2024 | −$158.6M | — |
| FY2023 | −$141.2M | — |
| FY2022 | $10.7M | — |
| FY2021 | −$138.4K | — |
| FY2020 | −$500.0K | — |
| FY2020 | −$500.0K | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$39.8M | — |
| Jun 2026 | −$39.2M | — |
| Mar 2026 | −$30.6M | — |
| Dec 2025 | −$40.9M | — |
| 20 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.8M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| MBX MBX Biosciences, Inc. compare | −$82.7M |
| NAMS NewAmsterdam Pharma Company N.V. | −$150.5M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$159.2M |
| PHVS Pharvaris N.V. compare | −$178.0M |
| XNCR Xencor, Inc. compare | −$205.8M |
| CLDX Celldex Therapeutics, Inc. compare | −$235.6M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$310.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement